Loading...
Loading...
KOD| Name | Value |
|---|---|
| Revenues | 26.7M |
| Cost of Revenue | 13.3M |
| Gross Profit | 13.3M |
| Operating Expense | 46.2M |
| Operating I/L | -46.2M |
| Other Income/Expense | 2.1M |
| Interest Income | 2.1M |
| Pretax | -44.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -44.1M |
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company specializing in the research, development, and commercialization of therapeutics for retinal diseases. The company's lead product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer currently in Phase IIb/III clinical study for the treatment of wet age-related macular degeneration (AMD) and other related conditions. Additionally, Kodiak Sciences Inc. has preclinical stage product candidates including KSI-501, a bispecific conjugate for retinal diseases with an inflammatory component, and KSI-601, a triplet inhibitor for the treatment of dry AMD.
